Clinical Trials
5
Active:0
Completed:2
Trial Phases
1 Phases
Not Applicable:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Not Applicable
5 (100.0%)New Treatment of Knee Osteoarthritis
Not Applicable
Recruiting
- Conditions
- Knee Osteoarthristis
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Symatese
- Target Recruit Count
- 134
- Registration Number
- NCT06611098
- Locations
- 🇱🇻
IRIS CRO, Riga, Latvia
Study on Knee Osteoarthritis
Not Applicable
Completed
- Conditions
- Knee Osteoarthritis
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Symatese
- Target Recruit Count
- 20
- Registration Number
- NCT06097988
- Locations
- 🇱🇻
Knohenfelds, Riga, Latvia
🇱🇻KRASTINS, Riga, Latvia
Evaluation of a HA Dermal Filler in the Treatment of Lip Deformity
Not Applicable
Recruiting
- Conditions
- Lip, CleftLip Scar
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Symatese
- Target Recruit Count
- 20
- Registration Number
- NCT05825170
- Locations
- 🇫🇷
Cabinet médical, Toulouse, Occitanie, France
🇫🇷Hôpital Roger Salengro, Lille, Nord, France
Evaluation of HA Dermal Fillers in the Treatment of Pathological Facial Lipoatrophy
Not Applicable
Completed
- Conditions
- Facial Lipoatrophy (FLA)
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Symatese
- Target Recruit Count
- 30
- Registration Number
- NCT05776836
- Locations
- 🇫🇷
THINKIN, Paris, Ile De France, France
🇫🇷Dermatology practice, Saint-Maur-des-Fossés, Ile De France, France
🇫🇷Palais de Flore, Lyon, Rhone, France
Evaluation of NEVELIA® in Terms of Safety and Efficacy for Third-degree Burns Treatment or Reconstructive Surgery
Not Applicable
- Conditions
- Third-degree BurnsReconstructive Surgery
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2014-03-17
- Lead Sponsor
- Symatese
- Target Recruit Count
- 30
- Registration Number
- NCT02089490
- Locations
- 🇫🇷
Centre François Xavier Michelet - CHU de Bordeaux, Bordeaux, France
News
Evolus Submits FDA Application for Evolysse Sculpt Mid-Face Dermal Filler
Evolus Inc. has submitted its final Premarket Approval application to the FDA for Evolysse Sculpt, an injectable hyaluronic acid gel designed to restore mid-face volume.